Skip to main content
Equibles
KYNB logo

KYNB · Kyntra Bio, Inc.

Track KYNB — free

Use KYNB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.54 +0.01 (+0.12%)
Rebalance outlook locked
Market Cap
$32.19M
Shares
4.05M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.53 Open$7.97 Day$7.92–8.65 52W close$6.46–12.43 Avg vol 30d14K Short int98K · 2.4% float · 14.2d Short vol48% Last earningsAug 13, 2026 DataJun 2025–Sep 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Jun 17, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 14, 2026 Est · unconfirmed · in 10 wks
Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.62M
Trailing 12 months
Net income (TTM)
$183.19M
Trailing 12 months
Revenue growth YoY
-209.3%
Year over year
Operating margin
-1,089.8%
Trailing 12 months
P / E (TTM)
0.2
Trailing earnings · reciprocal yield 569.8%
FCF yield
-118.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
-32.8%
Trailing year
Short interest
2.4%
Latest settlement · 14.2 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +17%
above
RSI (14) 72
overbought
MACD trend Positive
52-week position 35%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +22%
trailing
6-month return +22%
trailing
YTD return −3%
this year
Relative strength +7%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Distributing
-15% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.43% of float · ▲ +0.6% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
28 holders — near 1-yr low, contrarian setup
Squeeze score 67
elevated · 0–100
Fundamentals
Fair
Revenue growth −78%
Y/Y
EPS growth +482%
Y/Y
Free cash flow $-4.8M
Valuation P/E 0.2
below peers
Quant / Vol
risk profile
Very High
Volatility 54%
annualized · 1-yr
Max drawdown −48%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+17% Bullish
RSI (14)
72 Bearish
MACD trend
Positive Bullish
52-week position
35% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Distributing
-15% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.43% of float · ▲ +0.6% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
28 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $6 Now $9 · 35% Range high $12
vs 200-day avg +12% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KYNB
Kyntra Bio, Inc.
this stock
$32.19M -2.8% -78.3% 0.2 2.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +22.8% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +10.4% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $65.63B +25.5% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +411.4% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
28
% held
26.9%
Net QoQ
-35.7K sh
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
10
View
Short & Settlement
Short Interest Rising
Shares short
98.2K
Days to cover
14.2d
Change
+632 sh
View
Short Volume
Short vol %
48%
As of
Sep 2, 2026
Short Total
View
Fails to Deliver
FTD shares
465
Value
$3.3K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
51.1%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$6.4M
Net income (FY)
$183.5M
EPS diluted
$45.37
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 31, 2026
This year
12
View
Proposed Sales
Value
$13.1K
Shares
791
Filed
Jun 23, 2023
View
Earnings & Events
Earnings Calls
Last call
Aug 13, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 17, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
KYNB +5.2% +22.0% +21.5% +9.6% -2.9%
SPY -0.1% -0.6% +14.9% -0.3% +12.2%
vs SPY +5.4% +22.6% +6.6% +9.9% -15.1%
Key facts CIK 921299 CUSIP 31572Q881 13F (30d) 27 filings 26 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)